Dihydropyrazole azepine compound serving as Akt inhibitor
申请人:HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
公开号:US10654868B2
公开(公告)日:2020-05-19
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
imposes a new class of organophosphorus (OP)-inhibited cholinesterase reactivators by conceptualizing a family of asymmetric bisoximes with various reactivating scaffolds. Several novel nucleophilic warheads were investigated, putting forward 29 novel reactivating options, by evaluating their nucleophilicity and ability to directly decompose OP compounds. Adopting the so-called zwitterionic strategy, 17
目前的研究通过概念化具有各种重新激活支架的不对称双肟家族,提出了一类新的有机磷(OP)抑制胆碱酯酶重新激活剂。研究了几种新型亲核弹头,通过评估其亲核性和直接分解OP化合物的能力,提出了29种新型重新激活选项。采用所谓的两性离子策略,发现了 17 种单肟和 9 种双肟重激活剂,重点是双功能部分方法。将化合物与临床使用的标准品和其他已知的实验突出的再激活剂进行比较。我们的结果显然支持不对称双肟作为功效和多功能性方面领先的再激活剂的概念。这些排名靠前的化合物通过再激活动力学参数进行了详细表征,并评估了潜在的中枢神经系统可用性。突出显示的分子 、 和 具有各种重新激活弹头,超过了解磷定和几种著名的不带电重新激活剂的重新激活效力。还针对 OP 抑制的丁酰胆碱酯酶检查了主要候选药物的多功能性,结果显示与现有的临床解毒剂相比,其比率要高得多。
DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR